(SAVA) Cassava Sciences - Ratings and Ratios

Cassava Sciences, Inc. (NASDAQ: SAVA) is a clinical-stage biotechnology company focused on developing innovative therapies for neurodegenerative diseases, with a primary emphasis on Alzheimers disease. The companys lead therapeutic candidate, simufilam, is a small molecule drug designed to target the abnormal shape of the filamin A protein, which is implicated in neurodegeneration. Simufilam has completed a Phase 2 clinical trial, demonstrating potential to improve cognitive and functional outcomes in Alzheimers patients. Additionally, Cassava Sciences is advancing SavaDx, a proprietary blood-based biomarker/diagnostic tool aimed at detecting Alzheimers disease with greater accuracy and earlier than current methods. The company, originally incorporated in 1998 as Pain Therapeutics, Inc., rebranded as Cassava Sciences, Inc. in March 2019 to reflect its strategic shift toward Alzheimers disease research and development. Headquartered in Austin, Texas, Cassava Sciences is currently preparing for late-stage clinical trials and regulatory submissions for its lead programs.

From a technical perspective, SAVA shares are currently trading at $2.68 with a 20-day average volume of 1,619,049. The stocks short-term moving averages (SMA 20: $2.46, SMA 50: $2.52) suggest recent price stabilization near the lower end of its recent range. The SMA 200 of $16.68 highlights the significant decline in share price over the past year, likely reflecting market sentiment tied to clinical trial outcomes. The Average True Range (ATR) of 0.19 indicates relatively low volatility in recent trading sessions.

On the fundamental side, Cassava Sciences has a market capitalization of $125.09 million. The company currently operates with a price-to-book (P/B) ratio of 0.66, reflecting its pre-revenue stage and the markets valuation of its pipeline. The forward P/E ratio of 151.52 underscores investor expectations for future profitability, though this is contingent on successful clinical outcomes and regulatory approvals. The return on equity (RoE) of -10.60% highlights the companys ongoing R&D investments and operating losses as it advances its programs.

3-Month Forecast: Based on the provided data, SAVAs stock price is likely to remain range-bound in the near term, with potential upside driven by positive clinical updates or downside risk from further trial setbacks. Technically, the stock may test resistance near the SMA 50 ($2.52) and SMA 20 ($2.46), with limited upside momentum given the broader downtrend indicated by the SMA 200 ($16.68). Fundamentally, the companys progress toward Phase 3 trials for simufilam and regulatory milestones for SavaDx will be critical drivers of sentiment and valuation over the next quarter.